Bausch Health Companies Inc. announced the financing of its pending acquisition of XIIDRA and other ophthalmology assets through an offering of $1.4 billion aggregate principal amount of new senior secured notes and an incremental term loan facility.
AI Assistant
BAUSCH HEALTH COMPANIES INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.